



Diversity in COVID-19 vaccine testing helped assess safety and effectiveness.

COVID-19 affects everyone, so scientists made sure clinical trial participants for the vaccines were diverse. The clinical trials for the first two COVID-19 vaccines included Black (about 10% of participants) and Hispanic (about 20% of participants) people, older age groups (about 25%), and people with conditions such as obesity, diabetes, and heart and respiratory conditions. The U.S. study participants for the one-shot COVID-19 vaccine were 15% Hispanic/Latinx; 13% Black/African American; 6% Asian and 1% Native American.

New and future clinical trials will also include pregnant women and children under 12.

Source: Johns Hopkins Medicine



LENAWEE COUNTY
HEALTH DEPARTMENT